Anzutresgene Autoleucel

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous T-lymphocytes that are genetically modified with a lentiviral vector encoding a T-cell receptor (TCR) specific for the tumor-associated antigen (TAA) preferentially expressed antigen in melanoma (PRAME), with potential antineoplastic activity. Upon intravenous administration back into the patient, anzutresgene autoleucel specifically recognize and bind to PRAME expressed on cancer cells, which induces a cytotoxic T-lymphocyte (CTL)-mediated immune response against the PRAME-expressing cancer cells. PRAME is overexpressed by a variety of cancer cell types.

**Synonyms:** - ACTengine IMA203 - ANZUTRESGENE AUTOLEUCEL - Anzu-cel - Autologous PRAME-targeting TCR-engineered T-cells IMA203 - Autologous T-cell Receptor-engineered T-cells IMA203 - IMA 203 - IMA-203 - IMA203 - IMA203 Autologous T-lymphocytes - IMA203 T-cells